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clinical implications of basic research
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Research from both the bench and the clinic has 
provided increasing evidence for cross-talk be-
tween cholesterol metabolism and the immune 
system, providing a greater understanding of host 
response to infection and of the inflammatory 
components of cardiovascular disease, such as 
atherosclerosis. A recent example is research by 
Reboldi et al.1 showing that 25-hydroxycholesterol 
tightly regulates interleukin-1β, a potent cytokine.
The metabolite 25-hydroxycholesterol is an oxy-
sterol and is derived from cholesterol (Fig. 1A). 
Although it influences cholesterol homeostasis 
by means of the suppression of sterol regulatory 
element–binding proteins (SREBPs),2 its main 
effect appears to be on immune regulation. The 
most potent enzyme that transforms cholesterol 
into 25-hydroxycholesterol is cholesterol 25-hy-
droxylase (CH25H), which is prominently pro-
duced in monocytes, macrophages, and den-
dritic cells — the major cell types of the innate 
immune system synthesizing interleukin-1β. 
(CH25H is not expressed in the liver, the organ 
most active in synthesizing fatty acids and cho-
lesterol.) Mice lacking Ch25h have normal choles-
terol homeostasis (and also synthesize small 
amounts of 25-hydroxycholesterol) but have 
marked changes in their inflammatory response.1
The expression of CH25H is very strongly in-
duced by lipopolysaccharide, by type I interfer-
ons — important antiviral cytokines, one of 
which (interferon-β) is used to treat the inflam-
matory disease multiple sclerosis — and by viral 
infection, leading to increased concentrations of 
25-hydroxycholesterol.2 Reboldi et al. found that 
25-hydroxycholesterol mediates the inhibition of 
interleukin-1β induced by type I interferon.1 
More specifically, 25-hydroxycholesterol inhibits 
pro–interleukin-1β gene transcription as well 
as the inflammasome-mediated activation of 
interleukin-1β (Fig. 1B) by inhibiting the activa-
tion of SREBP. They found that the macrophages 
of Ch25h-knockout mice produce more inter-
leukin-1β when exposed to lipopolysaccharide 
and that this can be corrected by adding 25-hy-
droxycholesterol to the culture medium. The 
Ch25h-knockout mice were more susceptible than 
wild-type mice to lipopolysaccharide-induced 
lethality because of increased cytokine production.
A rare hereditary disease linking cholesterol 
metabolism and inflammation is mevalonate 
kinase deficiency. Mevalonate kinase is an early 
enzyme in the cholesterol pathway (Fig. 1A), and 
mutations in the mevalonate kinase gene cause 
a substantial reduction in enzyme activity. Pa-
tients with mevalonate kinase deficiency have 
lifelong recurring episodes of generalized in-
flammation with fever, mediated by cytokines 
such as interleukin-1β.3 Many patients with me-
valonate kinase deficiency have increased serum 
concentrations of IgA and IgD, and such in-
creased concentrations are also seen in mice de-
ficient in mevalonate kinase. The current hy-
pothesis is that defective protein isoprenylation 
(resulting in the diminished activation of guan-
osine triphosphatases [GTPases]) represents the 
link between a deficiency of mevalonate kinase 
and inflammation (Fig. 1A). But a deficiency in 
25-hydroxycholesterol is also a hypothetical link, 
the more so because 25-hydroxycholesterol also 
affects B cells. Ch25h-knockout mice also have 
increased serum levels of IgA. In addition, it is 
well known that viral infection (and vaccina-
tion) can provoke an inflammatory attack in per-
sons with mevalonate kinase deficiency.
Although a prompt inflammatory response is 
important in combating pathogens, an overly 
robust inflammatory response can damage the 
host and cause complications. Containing in-
flammation as soon as the infection is under 
control is therefore important. The inhibition 
of interleukin-1β by 25-hydroxycholesterol may 
represent a containment mechanism. Several 
studies have shown other inhibitory roles of 
25-hydroxycholesterol in cell models of viral in-
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fection, such as the inhibition of viral entry into 
the cell, and in the inhibition of viral replica-
tion.4 On the other hand, Gold et al.,5 using a 
systems biology approach, found that 25-hydroxy-
cholesterol amplifies inflammation. They found 
that Ch25h-knockout mice are more likely than 
wild-type mice to survive influenza, owing to 
less inflammatory damage. Additional studies 
are required to resolve the conundrum.
Statins, which are 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors 
(Fig. 1A), have been suggested to confer a sur-
vival benefit in influenza, although hard evi-
dence is still lacking. Diverse antiinflammatory 
effects, as well as some proinflammatory ef-
fects,2 have been attributed to statins. So far, 
however, the effects of either statins or hyper-
cholesterolemia on macrophage production of 
25-hydroxycholesterol are unclear.
Although questions remain unanswered, the 
study by Reboldi et al. offers insight into the 
role of 25-hydroxycholesterol in immunity and, 
more specifically, into the host response against 
viral infection. With the current multiple viral 
threats to populations around the world, new 
insights into the host response to viral infection 
— which may provide fodder for new clinical 
approaches to treatment — are more than 
 welcome.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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Figure 1. Derivation of 25-Hydroxycholesterol and the Inhibition of Interleukin-1β by 25-Hydroxycholesterol.
Panel A shows a simplified representation of the cholesterol pathway, with three activating enzymes indicated in green. Statins are inhib-
itors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The genetic defect in mevalonate kinase deficiency is located in 
mevalonate kinase. Panel B shows that the production of 25-hydroxycholesterol is induced by type I interferons, released during viral in-
fection, and also by lipopolysaccharide. The metabolite 25-hydroxycholesterol reduces the production of interleukin-1β by the inhibition 
of pro–interleukin-1β transcription and by the inhibition of activation of pro–interleukin-1β by inflammasomes. Ch25h denotes choles-
terol 25-hydroxylase, and Il1b the gene encoding interleukin-1β.
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